Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

In vivo architectonic stability of fully de novo designed protein-only nanoparticles

  • Céspedes, María Virtudes|||0000-0003-2956-5833
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Tatkiewicz, Witold
  • Sánchez Chardi, Alejandro|||0000-0002-8789-1883
  • Conchillo-Solé, Oscar|||0000-0003-4266-246X
  • Álamo, Patricia|||0000-0003-0510-5701
  • Xu, Zhikun
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
  • Corchero Nieto, José Luis|||0000-0002-6109-144X
  • Pesarrodona Roches, Mireia|||0000-0001-9669-8471
  • Cedano, Juan|||0000-0003-1380-8036
  • Daura i Ribera, Xavier|||0000-0001-9235-6730
  • Ratera Bastardas, Imma|||0000-0002-1464-9789
  • Veciana i Miró, Jaume|||0000-0003-1023-9923
  • Ferrer-Miralles, Neus|||0000-0003-2981-3913
  • Vázquez, Esther|||0000-0003-1052-0424
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Mangues, Ramon|||0000-0003-2661-9525
The fully de novo design of protein building blocks for self-assembling as functional nanoparticles is a challenging task in emerging nanomedicines, which urgently demand novel, versatile, and biologically safe vehicles for imaging, drug delivery, and gene therapy. While the use of viruses and virus-like particles is limited by severe constraints, the generation of protein-only nanocarriers is progressively reachable by the engineering of protein-protein interactions, resulting in self-assembling functional building blocks. In particular, end-terminal cationic peptides drive the organization of structurally diverse protein species as regular nanosized oligomers, offering promise in the rational engineering of protein self-assembling. However, the in vivo stability of these constructs, being a critical issue for their medical applicability, needs to be assessed. We have explored here if the cross-molecular contacts between protein monomers, generated by end-terminal cationic peptides and oligohistidine tags, are stable enough for the resulting nanoparticles to overcome biological barriers in assembled form. The analyses of renal clearance and biodistribution of several tagged modular proteins reveal long-term architectonic stability, allowing systemic circulation and tissue targeting in form of nanoparticulate material. This observation fully supports the value of the engineered of protein building blocks addressed to the biofabrication of smart, robust, and multifunctional nanoparticles with medical applicability that mimic structure and functional capabilities of viral capsids.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model

  • Álamo, Patricia|||0000-0003-0510-5701
  • Gallardo, Alberto|||0000-0002-2514-2027
  • Di Nicolantonio, Federica
  • Pavón Ribas, Miguel Ángel
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
  • Trias Folch, Manuel
  • Mangues, Ma Antonia|||0000-0002-1438-8515
  • López Pousa, Antonio|||0000-0003-1066-3951
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Vázquez, Esther|||0000-0003-1052-0424
  • Bardelli, Alberto
  • Céspedes, María Virtudes|||0000-0003-2956-5833
  • Mangues, Ramon|||0000-0003-2661-9525
Although all KRas (protein that in humans is encoded by the KRas gene) point mutants are considered to have a similar prognostic capacity, their transformation and tumorigenic capacities vary widely. We compared the metastatic efficiency of KRas G12V (Kirsten rat sarcoma viral oncogene homolog with valine mutation at codon 12) and KRas G13D (Kirsten rat sarcoma viral oncogene homolog with aspartic mutation at codon 13) oncogenes in an orthotopic colorectal cancer (CRC) model. Following subcutaneous preconditioning, recombinant clones of the SW48 CRC cell line [Kras wild-type (Kras WT)] expressing the KRas G12V or KRas G13D allele were microinjected in the mouse cecum. The percentage of animals developing lymph node metastasis was higher in KRas G12V than in KRas G13D mice. Microscopic, macroscopic, and visible lymphatic foci were 1.5- to 3.0-fold larger in KRas G12V than in KRas G13D mice (P < 0.05). In the lung, only microfoci were developed in both groups. KRas G12V primary tumors had lower apoptosis (7.0 ± 1.2 vs. 7.4 ± 1.0 per field, P = 0.02), higher tumor budding at the invasion front (1.2 ± 0.2 vs. 0.6 ± 0.1, P = 0.04), and a higher percentage of C-X-C chemokine receptor type 4 (CXCR4)-overexpressing intravasated tumor emboli (49.8 ± 9.4% vs. 12.8 ± 4.4%, P < 0.001) than KRas G13D tumors. KRas G12V primary tumors showed Akt activation, and β5 integrin, vascular endothelial growth factor A (VEGFA), and Serpine-1 overexpression, whereas KRas G13D tumors showed integrin β1 and angiopoietin 2 (Angpt2) overexpression. The increased cell survival, invasion, intravasation, and specific molecular regulation observed in KRas G12V tumors is consistent with the higher aggressiveness observed in patients with CRC expressing this oncogene.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Targeting low-density lipoprotein receptors with protein-only nanoparticles

  • Xu, Zhikun
  • Céspedes, María Virtudes|||0000-0003-2956-5833
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Álamo, Patricia|||0000-0003-0510-5701
  • Pesarrodona Roches, Mireia|||0000-0001-9669-8471
  • Mangues, Ramon|||0000-0003-2661-9525
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Ferrer-Miralles, Neus|||0000-0003-2981-3913
Low-density lipoprotein receptors (LDLR) are appealing cell surface targets in drug delivery, as they are expressed in the blood-brain barrier (BBB) endothelium and are able to mediate transcytosis of functionalized drugs for molecular therapies of the central nervous system (CNS). On the other hand, brain-targeted drug delivery is currently limited, among others, by the poor availability of biocompatible vehicles, as most of the nanoparticles under development as drug carriers pose severe toxicity issues. In this context, protein nanoparticles offer functional versatility, easy and cost-effective bioproduction, and full biocompatibility. In this study, we have designed and characterized several chimerical proteins containing different LDLR ligands, regarding their ability to bind and internalize target cells and to self-organize as viral mimetic nanoparticles of about 18 nm in diameter. While the self-assembling of LDLR-binding proteins as nanoparticles positively influences cell penetration in vitro, the nanoparticulate architecture might be not favoring BBB crossing in vivo. These findings are discussed in the context of the use of nanostructured materials as vehicles for the systemic treatment of CNS diseases.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Formulating tumor-homing peptides as regular nanoparticles enhances receptor-mediated cell penetrability

  • Xu, Zhikun
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Roldán, Mónica
  • Mangues, Ramon|||0000-0003-2661-9525
  • Sánchez Chardi, Alejandro|||0000-0002-8789-1883
  • Ferrer-Miralles, Neus|||0000-0003-2981-3913
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Vázquez, Esther|||0000-0003-1052-0424
Homing peptides are exploited in nanomedicine to functionalize either free drugs or nanostructured materials used as drug carriers. However, the influence of multivalent versus monovalent peptide presentation on the interaction with the receptor and on the consequent intracellular delivery of the associated cargo remains poorly explored. By using a tumor-homing peptide (T22) with regulatable self-assembling properties we have investigated here if its display in a either a monomeric form or as multimeric, self-assembled protein nanoparticles might determine the efficacy of receptor-mediated penetrability into target cells. This has been monitored by using a fluorescent cargo protein (iRFP), which when fused to the homing peptide acts as convenient reporter. The results indicate that the nanoparticulate protein versions are significantly more efficient in mediating receptor-dependent uptake than their unassembled counterparts. These finding stresses an additional benefit of nanostructured materials based on repetitive building blocks, regarding the multivalent presentation of cell ligands that facilitate cell penetration in drug delivery applications.
Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

Towards Protein-Based Viral Mimetics for Cancer Therapies

  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Céspedes, María Virtudes|||0000-0003-2956-5833
  • Vázquez, Esther|||0000-0003-1052-0424
  • Ferrer-Miralles, Neus|||0000-0003-2981-3913
  • Mangues, Ramon|||0000-0003-2661-9525
  • Villaverde, Antonio|||0000-0002-2615-4521
High resistance and recurrence rates, along with elevated drug clearance, compel the use of maximum tolerated drug doses in cancer therapy, resulting in high-grade toxicities and limited clinical applicability. Promoting active drug accumulation in tumor tissues would minimize such issues and improve therapeutic outcomes. A new class of therapeutic drugs suitable for the task has emerged based on the concept of virus-mimetic nanocarriers, or 'artificial viruses.' Among the spectrum of materials under exploration in nanocarrier research, proteins offer unparalleled structural and functional versatility for designing viruslike molecular vehicles. By exhibiting 'smart' functions and biomimetic traits, protein-based nanocarriers will be a step ahead of the conventional drug-protein conjugates already in the clinics in ensuring efficient delivery of passenger antitumor drugs.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Subcutaneous preconditioning increases invasion and metastatic dissemination in mouse colorectal cancer models

  • Álamo, Patricia|||0000-0003-0510-5701
  • Gallardo, Alberto|||0000-0002-2514-2027
  • Pavón Ribas, Miguel Ángel
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
  • Trias, Manuel
  • Mangues, Ma Antonia|||0000-0002-1438-8515
  • Vázquez, Esther|||0000-0003-1052-0424
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Mangues, Ramon|||0000-0003-2661-9525
  • Céspedes, María Virtudes|||0000-0003-2956-5833
Mouse colorectal cancer (CRC) models generated by orthotopic microinjection of human CRC cell lines reproduce the pattern of lymphatic, haematological and transcoelomic spread but generate low metastatic efficiency. Our aim was to develop a new strategy that could increase the metastatic efficiency of these models. We used subcutaneous implantation of the human CRC cell lines HCT116 or SW48 prior to their orthotopic microinjection in the cecum of nude mice (SC+ORT). This subcutaneous preconditioning significantly enhanced metastatic dissemination. In the HCT116 model it increased the number and size of metastatic foci in lymph nodes, lung, liver and peritoneum, whereas, in the SW48 model, it induced a shift from nonmetastatic to metastatic. In both models the number of apoptotic bodies in the primary tumour in the SC+ORT group was significantly reduced compared with that in the direct orthotopic injection (ORT) group. Moreover, in HCT116 tumours the number of keratin-positive tumour buddings and single epithelial cells increased at the invasion front in SC+ORT mice. In the SW48 tumour model, we observed a trend towards a higher number of tumour buds and single cells in the SC+ORT group but this did not reach statistical significance. At a molecular level, the enhanced metastatic efficiency observed in the HCT116 SC+ORT model was associated with an increase in AKT activation, VEGF-A overexpression and downregulation of β1 integrin in primary tumour tissue, whereas, in SW48 SC+ORT mice, the level of expression of these proteins remained unchanged. In summary, subcutaneous preconditioning increased the metastatic dissemination of both orthotopic CRC models by increasing tumour cell survival and invasion at the tumour invasion front. This approach could be useful to simultaneously study the mechanisms of metastases and to evaluate anti-metastatic drugs against CRC.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Stroma-derived HGF drives metabolic adaptation of colorectal cancer to angiogenesis inhibitors

  • Mira, Alessia
  • Morello, Virginia
  • Céspedes, María Virtudes|||0000-0003-2956-5833
  • Perera, Timothy
  • Comoglio, Paolo M.
  • Mangues, Ramon|||0000-0003-2661-9525
  • Michieli, Paolo
The role of paracrine Hepatocyte Growth Factor (HGF) in the resistance to angiogenesis inhibitors (AIs) is hidden in xenograft models because mouse HGF fails to fully activate human MET. To uncover it, we compared the efficacy of AIs in wild-type and human HGF knock-in SCID mice bearing orthotopic human colorectal tumors. Species-specific HGF/MET signaling dramatically impaired the response to anti-angiogenic agents and boosted metastatic dissemination. In cell-based assays mimicking the consequences of anti-angiogenic therapy, colorectal cancer cells were completely resistant to hypoxia but extremely sensitive to nutrient deprivation. Starvation-induced apoptosis could be prevented by HGF, which promoted GLUT1-mediated glucose uptake, sustained glycolysis and activated autophagy. Pharmacological inhibition of GLUT1 in the presence of glucose killed tumor cells as effectively as glucose deprivation, and this effect was antagonized by HGF. Concomitant targeting of GLUT1 and HGF potently suppressed growth and dissemination of AI-resistant human tumors in human HGF knock-in SCID mice without exacerbating tumor hypoxia. These data suggest that stroma-derived HGF protects CRC cells against glucose starvation-induced apoptosis, promoting resistance to both AIs and anti-glycolytic agents. Combined inhibition of glucose metabolism and HGF/MET signaling ('anti-METabolic therapy') may represent a more effective CRC treatment compared to utterly blocking tumor blood supply.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Enhanced cell migration and apoptosis resistance may underlie the association between high SERPINE1 expression and poor outcome in head and neck carcinoma patients

  • Pavón, Miguel Ángel|||0000-0003-3677-5329
  • Arroyo Solera, Irene|||0000-0003-0425-1483
  • Téllez Gabriel, Marta|||0000-0002-0895-2677
  • León i Vintró, Xavier|||0000-0001-6286-630X
  • Virós, David
  • López, Montserrat
  • Gallardo, Alberto|||0000-0002-2514-2027
  • Céspedes, María Virtudes|||0000-0003-2956-5833
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
  • López Pousa, Antonio|||0000-0003-1066-3951
  • Mangues, Ma Antonia|||0000-0002-1438-8515
  • Quer, Miquel|||0000-0003-2563-6729
  • Barnadas i Molins, Agustí|||0000-0002-0429-1349
  • Mangues, Ramon|||0000-0003-2661-9525
High SERPINE1 expression is a common event in head and neck squamous cell carcinoma (HNSCC); however, whether it plays a role in determining clinical outcome remains still unknown. We studied SERPINE1 as a prognostic marker in two HNSCC patient cohorts. In a retrospective study (n = 80), high expression of SERPINE1 was associated with poor progression-free (p = 0.022) and cancer-specific (p = 0.040) survival. In a prospective study (n = 190), high SERPINE1 expression was associated with poor local recurrence-free (p = 0.022), progression-free (p = 0.002) and cancer-specific (p = 0.006) survival. SERPINE1 expression was identified as an independent risk factor for progression-free survival in patients treated with chemo-radiotherapy or radiotherapy (p = 0.043). In both patient cohorts, high SERPINE1 expression increased the risk of metastasis spread (p = 0.045; p = 0.029). The association between SERPINE1 expression and survival was confirmed using the HNSCC cohort included in The Cancer Genome Atlas project (n = 507). Once again, patients showing high expression had a poorer survival (p < 0.001). SERPINE1 over-expression in HNSCC cells reduced cell proliferation and enhanced migration. It also protected cells from cisplatin-induced apoptosis, which was accompanied by PI3K/AKT pathway activation. Downregulation of SERPINE1 expression had the opposite effect. We propose SERPINE1 expression as a prognostic marker that could be used to stratify HNSCC patients according to their risk of recurrence.